Dr. Ralph Defronzo talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about SGLT-2, GLP-1, and the drugs he recommends despite standard practice.
Dr. Ralph Defronzo, MD is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Diabetes Center in San Antonia, Texas. Dr. Defronzo is also Deputy Director of the Texas Diabetes Institute.
Transcript of this video segment:
Steve Freed:You were one of the first to use triple therapy. Certainly a more aggressive attitude. Now we have drugs that actually prevent or reduce your risk for death. Now were coming out, were finding out the SGLT-2s may cause amputation of your toes. It may cause other issues. I dont think theres a drug on the planet that doesnt have side effects. But were not going to die from the loss of a toe. What are your thoughts even when it comes to SGLT-2s? I know theyre fairly expensive right now. Competition hopefully will reduce that. What are your thoughts about the SGLT-2 drugs and the GLP-1s?
Dr. Defronzo:Let me just back up before I talk about this amputation issue, because its going to be very controversial. To me, Ive always been a strong believer that you need to understand what causes type 2 diabetes. NIH spends millions and millions of dollars to help us try to define what causes the disease. If you know what causes the disease, you ought to use medications to reverse the problem. Sulfonylureas clearly dont do that. In my opinion, these drugs, other than cost, really should not be being used in our diabetic patients. We have much better armor material. So if I had to list the drugs, and this may be a little bit different from what other people tell you. I would put a tie between GLP-1 receptor agonist and pioglitazone. And very close to those two, I would put SGLT-2 inhibitor. Id put Metformin as a good drug but lower down. Those are my four good drugs. Then way down, Id put DPP-4 inhibitors and I just dont use sulfonylurea drugs. I dont believe that theres any need for these drugs. Youd have to be very hard pressed that people could not afford any other drug before Im going to resort to using sulfonylurea drugs. Weve done a very large study with triple therapy. Its now into its 5th year. We use a combination of pioglitazone, a GLP-1 receptor agonist, and Metformin. Because when we started these studies, SGLT-2 inhibitors were not around. I can tell you now, the results are phenomenal. These people have three years later normal beta-cell function. They have a 60% improvement in insulin sensitivity. They lose weight. Theres minimal hypoglycemia. We just published a very large study inDiabetes Care, its called the Qatar Study, where theyre going to play the World Cup. We took people who had failed completely on Metformin and sulfonylurea. Their A1C was 10.1. They had ten and a half duration of this disease. We added a GLP-1 receptor agonist plus pioglitazone. A year and a half later, they have an A1C of 6. So, the beta cells, Id rather say, theyre not dead, theyre hibernating. People dont recognize that the TZDs have a huge effect on the beta cell. GLP-1 receptor agonists have a huge effect on the beta cell. And then pioglitazone also has a good insulin sensitizing effect. If I had to do this study over again, I actually would replace the Metformin with the SGLT-2 inhibitor. But these are all good drugs and docs need to learn how to mix and match them. Then they also need to remember that even though you start on two or three drugs, or even you start on one drug, you need to follow the patient to see what happens. If you get a gratifying response, great. But if you dont, then you need to move on quickly, either adding one or two additional drugs.
Steve Freed:Now, you had mentioned, if you go back 50 years, we had one oral drug. Today, we have a couple million possible combinations if you include insulin in there. What you see coming down the pike as far as the future because it used to be simple. You go to your doctor, and he gives you a prescription for sulfonylurea. Today, theres so many options and so many new drugs that each of them has side effects. Theyre all a little bit different. Theyre certainly better than what we had. How do you teach a physician, what possible combination he should use? Is it just trial-and-error?
Dr. Defronzo:Well, I think for endocrinologists, its a little bit easier because this is our job. I think the real problem is amongst primary care physicians because they have to learn all of these new diabetes drugs. Then they have G.I. problems. They have to learn all of these new G.I. drugs. Then they have people presenting with arthritis and collagen vascular disease. Then we have this whole new plethora of immuno-suppressive drugs. I feel sorry in a certain way for the primary care physician because hes supposed to be an expert in everything. Well, thats not possible. The good part is we have very good medications. So thats an advantage. Sometimes I see patients coming to me, I wonder why are they on these drugs when theyre not well controlled, when there are better drugs. It sounds easy for us. I see a patient literally in 10 to 15 minutes, I can handle all the problems. I know instantaneously what to do with glucose, lipids, blood pressure, and cardiovascular issues. Thats basically the major part of diabetes cardiovascular hypertension treatment. And since Im board certified in nephrology as well, I know if they get kidney problems what to do. So for me its very easy to take care of diabetic patients. Its not so easy for primary care physicians and then on top of all of that, we have cost. These newer drugs are really quite expensive. Also, if you prescribe a drug thats not on the patients formulary and he goes to pick it up and its $500, believe me you havent prescribed any drug, because hes not going to get it. Even though, the docs may understand what drugs do and what are the good ones, not always can you prescribe them for your patients.
Return to main page.
Read the rest here:
Dr. Ralph Defronzo Part 3, Diabetes Medications - Diabetes In Control
- Fresh health warning over common additive used in thousands of ultra-processed foods including mayo and bread - Daily Mail - April 25th, 2024
- Vertex jumps to TreeFrog to enhance production of Type 1 diabetes cell therapy candidates - FiercePharma - April 25th, 2024
- Spotting the warning signs of diabetes in your pets - CBC.ca - April 25th, 2024
- Lexington-Fayette County health department organizing weekend diabetes awareness expo - WEKU - April 25th, 2024
- Preventive effects of SGLT2 inhibitors on incident hypertension in patients with diabetes who do not have hypertension ... - Nature.com - April 25th, 2024
- Curbing the Price of Novel Diabetes and Obesity Medications - Yale School of Medicine - April 25th, 2024
- Stanford Health closing Livermore Diabetes and Bariatric Center - Pleasanton Weekly - April 25th, 2024
- The association of ALT to HDL-C ratio with type 2 diabetes in 5074 years old adults: a population-based study ... - Nature.com - April 25th, 2024
- VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO ... - PR Newswire - April 25th, 2024
- Understanding the Complexity of Hyperglycemic Emergencies: Exploring the Influence of the Type and Duration of ... - Cureus - April 25th, 2024
- What Every Parent Should Know About Raising a T1D Kid - Health Central - April 25th, 2024
- Healthy Living & Diabetes Awareness Fair 2024 - University of New Mexico - April 25th, 2024
- New findings on pancreatic anatomy may affect diabetes research and treatment - Medical Xpress - April 25th, 2024
- The role of yogurt in diabetes and obesity prevention - News-Medical.Net - April 25th, 2024
- How exercising outdoors can prevent depression and diabetes - inews - April 25th, 2024
- Heart of the Valley: Valley woman discusses how she improved her health following diabetes diagnosis - KRGV - April 25th, 2024
- The Right Amount of Sleep Could Help Prevent This Extremely Common Disease - Inverse - April 25th, 2024
- 'Bread and Butter': Societies Issue T2D Management Guidance - Medscape - April 25th, 2024
- She was fired after not endorsing Splenda-filled salads to people with diabetes. Why? - The Guardian - April 25th, 2024
- Glycemic index of diets: importance beyond diabetes control - The Hindu - April 25th, 2024
- 1 woman thought she was destined for diabetes. This 1 realization helped her lose 70 pounds - Yahoo! Voices - March 29th, 2024
- Franciscan Health offering diabetes education at local churches - The Times of Northwest Indiana - March 29th, 2024
- For diabetes patients, needle-free insulin injections are on the way - ScienceBlog.com - March 29th, 2024
- Las Vegas nonprofit hosting health workshop specifically aimed at local Latinos - KTNV 13 Action News Las Vegas - March 29th, 2024
- How Often Do You Really Need to Check Your Blood Sugar Levels? - WSJ - The Wall Street Journal - March 29th, 2024
- Unintended Effects of Caps on Insulin Out-of-Pocket Costs - Managed Healthcare Executive - March 29th, 2024
- Study: Pompe treatment Nexviazyme isn't linked to new or worsening... - Pompe Disease News - March 29th, 2024
- A Smoker With New-Onset Pain in Both Feet - Medscape Reference - March 29th, 2024
- Pre-diabetes leads to Type 2 diabetes; Here's how to prevent and reverse it - WXII12 Winston-Salem - March 29th, 2024
- 'From Interpretation to Action': Using CGM to Manage T2D - Medscape - March 29th, 2024
- March: diabetes-kidney | News and features - University of Bristol - March 29th, 2024
- Health centers attempt to prevent diabetes - WTVM - March 29th, 2024
- Beyond Meat Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart ... - Yahoo Finance - March 29th, 2024
- Beyond Meat Launches Revamped Plant-Based Crumbles, Earning American Heart and Diabetes Association ... - vegconomist - the vegan business magazine - March 29th, 2024
- Ypsomed hands off insulin pen needle business to focus on smart pump, autoinjector development - Fierce Biotech - March 29th, 2024
- Take the online diabetes test that could help save your life - NBC Connecticut - March 29th, 2024
- Study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes - News-Medical.Net - March 29th, 2024
- Risk prediction using genes and gut bacteria can improve early detection of diseases like type 2 diabetes - Medical Xpress - March 29th, 2024
- On a Healthy Vegan Diet, I've Healed My Liver, Reversed Type 2 Diabetes, and Lost 35 Pounds - Forks Over Knives - March 29th, 2024
- Study Links Diet, Diabetes, and Alzheimers - Neuroscience News - March 29th, 2024
- Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be - Yahoo Finance - March 18th, 2024
- Doctor warns of strange telltale sign of diabetes which can appear on the legs - The Mirror - March 18th, 2024
- Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies - News-Medical.Net - March 18th, 2024
- Popular diabetes and weight loss drugs often hard to get for people who need them - NBC News - March 18th, 2024
- Your Health Matters: The ABCs of diabetes - The Globe | News, weather, sports from Worthington, Minnesota - The Globe - March 18th, 2024
- The Link Between Pancreatic Cancer and Diabetes - Cedars-Sinai - March 18th, 2024
- Nikita Kuzmin diabetes: what was he holding in the CBB house? - Cosmopolitan UK - March 18th, 2024
- FDA Approves Rezdiffra, the First Drug for Diabetes-Related Liver Disease - diaTribe Foundation - March 18th, 2024
- He took up running rather than take diabetes medication. It worked - South China Morning Post - March 18th, 2024
- Can Eating Yogurt Really Reduce Your Risk of Diabetes? - Health.com - March 18th, 2024
- Even short periods of diabetes remission are linked to lower risk of heart attack and stroke - The BMJ - March 18th, 2024
- Kidney stone risk factors and how type 2 diabetes medication may help - WECT - March 18th, 2024
- 'Making the Invisible Visible': CGMs Offer Insights for T2D - Medscape - March 18th, 2024
- Novo Nordisk Discontinues Insulin Medication After Cutting Its Price - The American Prospect - March 18th, 2024
- Infographic: Where GLP-1s Work Now -- and What's Coming - Medscape - March 18th, 2024
- Intermountain Health Experts Say Education Key to Prevention of Type 2 Diabetes | PRUnderground - PR Underground - March 18th, 2024
- International body recommends more sensitive test to indicate risk of developing diabetes - The Hindu - March 18th, 2024
- The importance of knowing your A1C level - KSAT San Antonio - March 18th, 2024
- Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... - Business Wire - January 9th, 2024
- Diffuse Alveolar Hemorrhage Occurring Suddenly in a Diabetic Patient With Asthma Exacerbation - Cureus - January 9th, 2024
- Virginia Tech researchers find drugs used to treat Type 2 diabetes reduce alcohol cravings - WRIC ABC 8News - January 9th, 2024
- FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss - CNN - January 9th, 2024
- Glycemic control and cardiovascular outcomes in patients with diabetes and coronary artery disease according to ... - Cardiovascular Diabetology - January 9th, 2024
- Insulin price cap: More Americans will now pay no more than $35 - USA TODAY - January 9th, 2024
- Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for cosmetic reasons instead of for diabetes and obesity - Fortune - January 9th, 2024
- No Increased Risk of Suicidal Ideation With GLP-1 Drugs - Medpage Today - January 9th, 2024
- Ask the Doctors | New research being conducted to treat diabetes - Eureka Times-Standard - January 9th, 2024
- Salivary Chloride Intracellular Channel 1 (CLIC1) as a Hub of Gene-Gene Interactome of Periodontitis With Diabetes ... - Cureus - January 9th, 2024
- Why Omada's CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program - MedCity News - January 9th, 2024
- Researchers find drugs used to treat type 2 diabetes and obesity reduce alcohol cravings - Medical Xpress - January 9th, 2024
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different ... - Nature.com - January 9th, 2024
- CV Safety Profile of TheracosBio's BRENZAVVY (bexagliflozin) Confirmed in Research Published in Diabetes ... - Business Wire - January 9th, 2024
- 6 "Bad" Fruits You Should Be Eating When You Have Diabetes, According to Dietitians - EatingWell - January 9th, 2024
- Children of Women with Type 1 Diabetes Have Increased Heart Defect Risk - Inside Precision Medicine - January 9th, 2024
- Transforming Corporate Health: Fitterfly's Success in Tackling Diabetes and Weight Issues - Business Standard - January 9th, 2024
- Ozempic and weight loss | News and views - Diabetes UK - January 9th, 2024
- Drugs used to treat Type 2 diabetes reduce alcohol cravings - ScienceBlog.com - January 9th, 2024
- People taking Wegovy and Ozempic have lower risk of suicidal thoughts vs. older drugs, study finds - ABC News - January 9th, 2024
- For Those With Diabetes On Medicare Part D, Insulin Is $35...If Its Covered - Forbes - October 27th, 2023
- Biologist Douglas Melton: I was studying frogs until my son was diagnosed with diabetes then I started looking for a cure - EL PAS USA - October 27th, 2023